The Temporary Authorisation for Use allows patients to benefit from pharmaceutical specialities whereas they do not have any marketing authorization, provided that they are intended for the treatment of serious or orphan diseases and in the absence of appropriate treatment. But how to manage your ATU especially in France?
Proud to bring inspirational speakers from across the globe.
CEO and Founder of Adalys
Anne Grassin combines over 10 years of experience project and team management with emphasis on delivering solutions and services for the pharmaceutical industry.
Senior Director Drug Development and Vigilance, PharmaLex
Patrick Larcier has a wealth of experience focusing on the development of drugs and biologics, as well as Companion Diagnostic tests. His expertise lies in the design and implementation of regulatory strategies at all stages of clinical development for complex and innovative medicinal products, interactions with EU Regulatory Agencies , co-development of IVDs and drugs.